Reference Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

Ref Type
PMID
Authors
Title Kanjinti (Trastuzumab-anns) FDA Drug Label
URL https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761073
Abstract Text

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Treatment Approach
Gene Name Source Synonyms Protein Domains Gene Description Gene Role
Therapy Name Drugs Efficacy Evidence Clinical Trials
Trastuzumab-anns Trastuzumab-anns 0 0
Drug Name Trade Name Synonyms Drug Classes Drug Description
Trastuzumab-anns Kanjinti ABP 980 HER2 (ERBB2) Antibody 72 Kanjinti (Trastuzumab-anns) is a Herceptin (trastuzumab) biosimilar that binds to Erbb2 (Her2), which potentially results in anti-tumor immune response against Erbb2 (Her2)-positive tumors (PMID: 31798693). Kanjinti (Trastuzumab-anns) is FDA approved for use in patients with Erbb2 (Her2) overexpressing breast, metastatic gastric or gastroesophageal junction adenocarcinoma (FDA.gov).
Gene Variant Impact Protein Effect Variant Description Associated with drug Resistance
Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References